ERBB2 and cholangiocarcinoma: Overexpression and amplification of HER2/3 are frequent in CCA, but more so in extrahepatic CCA (eCCA, ≈15%) than in iCCA (≈7%), which has led to the suggestion that they can be good targets for inhibition [68].